WO2023248008 - DEGRON FUSION CONSTRUCTS
National phase entry:
Publication Number
WO/2023/248008
Publication Date
28.12.2023
International Application No.
PCT/IB2023/000371
International Filing Date
20.06.2023
Title **
[English]
DEGRON FUSION CONSTRUCTS
[French]
CONSTRUCTIONS DE FUSION DE DÉGRONS
Applicants **
VECTORY B.V.
Inventors
SANDERS, Barbara
POS, Wouter
KONSTANTINOVA, Pavlina
VAN DEVENTER, Sander
SPITS, Menno
Priority Data
63/366,665
20.06.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4822 | |
| EPO | Filing, Examination, Granting | 71944 | |
| Japan | Filing, Examination, Granting | 4335 | |
| South Korea | Filing, Examination, Granting | 6133 | |
| USA | Filing, Examination, Granting | 30590 |
Total:
117,824
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present application concerns degrons, compositions, and chimeric molecules comprising the degrons, especially fusion proteins of a degron and a binding moiety, and methods of using such degrons and chimeric molecules, especially for treating diseases caused by protein accumulation and/or aggregation, especially neurodegenerative or neuromuscular diseases like ALS or Huntington's disease. The binding moiety is preferably antibody, in particular an scFv fragment specific for different targets. The degrons and chimeric molecules provided herein effectively target proteins and/or aggregates, like TDP-43 or huntingtin, for degradation. In the application, specific degrons were fused to scFv targeting human TDP-43 and human huntingtin (HTT).[French]
La présente invention concerne des dégrons, des compositions et des molécules chimériques comprenant les dégrons, ainsi que des méthodes d'utilisation des dégrons et des molécules chimériques.